Expansions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Expansions
A roundup of manufacturing and service expansions

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

A roundup of manufacturing and service expansions.

New York (Aug. 20)ImClone Systems received approval from the US Food and Drug Administration for its second facility to manufacture "Erbitux" (cetuximab). The approval to manufacture Erbitux in the new 250,000-ft.2 multisuite manufacturing facility, referred to as BB50, more than doubles ImClone's total available production-volume capacity.

San Diego, CA (Aug. 16)Pharmatek Laboratories added cytotoxic and high-potent drug development capabilities to its pharmaceutical chemistry development services. Cytotoxic and high-potent services include analytical method development, preformulation testing, formulation development, manufacturing for early-phase clinical trials, release testing, and stability testing and storage.

Cramlington, UK (Aug. 23)Aesica opened its new pilot plant at Cramlington to manufacture and supply small-scale quantities of clinical compounds (10–100 kg).

Toronto, ON, Canada (Aug. 13)Microbix Biosystems established a team of experts to help manufacturers boost their production of influenza vaccine. The "Special Workgroup for Applied Technology Transfer" or "SWATT" group, working with the company's "VirusMax" technology, spends several weeks at each facility to help implement the technology and train personnel.

The VirusMax technology is designed to increase the virus yield from eggs by effectively recovering the virus. "Our technology can be installed very quickly, and with limited capital costs into existing manufacturing processes," said William J. Gastle, CEO of Microbix, in a prepared statement. According to the company, the technology has been shown to double vaccine production.

Mississauga, Ontario, Canada (Aug. 1)Alphora Research recently expanded to include a 14,000-ft2 facility to support a new pilot-plant facility. The pilot-plant is currently under construction and is targeted for completion by the end of 2007. This facility includes 200-L and 400-L glass-lined reactors, which includes equipment for cryogenic reactions. Support functions are also being installed, including warehousing and quality control capabilities.

Kankakee, IL (Aug. 1)CSL Behring will invest $15 million to expand its manufacturing facility by adding a high-speed, single-dose syringe-filling line. Plans call for the line to be operational in 2010, when the company intends to contract with its sister company, CSL Biotherapies, to provide filling and packaging services for seasonal influenza vaccine.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here